Scientific Sources & Reference Registry
Deterministic volumetric math requires no opinion, but non-mathematical claims (regulatory status, chemical structure, vial stability, and syringe graduation specs) must adhere to primary documentation. Below is our catalog of primary sources.
Evidence Hierarchy & Verification Methodology
To uphold rigorous E-E-A-T and YMYL scientific standards, every factual claim regarding pharmacology, diluent properties, vial beyond-use dates, and regulatory status is grounded in a verified hierarchy of primary documentation. We prioritize official FDA-approved prescribing information on DailyMed, formal CDER safety communications, and United States Pharmacopeia (USP) compounding compendia (USP <797> and <659>). Device dimensions and syringe volumetric graduations derive strictly from manufacturer technical sheets and international standards (Embecta/BD U-100 specifications, ISO 8537, and ISO 9626).
When discussing investigational peptides lacking FDA human approval (such as Retatrutide, BPC-157, or MOTS-c), we cite peer-reviewed clinical trials or primary pharmacology publications indexed in PubMed/MEDLINE. We explicitly distinguish between human clinical trial data and preclinical animal studies. We maintain a zero-tolerance policy against citing vendor sales blogs, bodybuilding community forums, social media channels, or unsubstantiated marketing literature.
Date Integrity: Every source record documents an immutable accessed verification date (YYYY-MM-DD) confirming the exact date our editorial team retrieved and audited the source document against active regulatory databases.
FDA Prescribing Labels & Package Inserts
FDA prescribing label outlining official pen formulation concentrations and storage parameters.
FDA prescribing information for pre-filled multi-dose semaglutide delivery pen.
FDA label outlining dual GIP/GLP-1 receptor agonist dosing strengths and storage.
FDA prescribing details for pre-filled single-dose pens and single-dose vials.
Prescribing information for GHRH analogue reconstitution with sterile diluent.
FDA prescribing information for synthetic melanocortin receptor agonist.
Sterile multi-dose diluent specification containing 0.9% (9 mg/mL) benzyl alcohol preservative.
Single-dose sterile water for injection without antimicrobial agents or added buffers.
Multi-dose isotonic diluent containing 9 mg/mL sodium chloride and 0.9% (9 mg/mL) benzyl alcohol.
Geref (sermorelin acetate) FDA approval in 1997 for diagnostic use and pediatric GHD; discontinued by applicant for commercial reasons, not safety or efficacy.
FDA Regulatory Communications & Safety Alerts
Official regulatory shortage tracker governing federal compounding boundaries under FD&C Act sections 503A/503B.
FDA safety alert detailing risks of unapproved compounded GLP-1 drugs, dosing errors, lack of pre-market review, improper cold-chain shipping temperatures, and recommendation to discard multi-dose sterile vials 28 days after first puncture.
FDA Category 2 classification covering safety considerations for BPC-157, AOD-9604, and CJC-1295.
Pharmacopeial & Compounding Standards (USP)
Standards for beyond-use dates (BUD), refrigeration controls (2°C–8°C), and multi-dose sterility.
Official compendial definitions for cold storage (2°C to 8°C), freezer conditions, and protection from light and freezing.
International dimensional specification governing outer diameter gauge designations (10G–34G) and wall thicknesses for rigid stainless steel hypodermic needle tubing.
Technical specifications for RP-HPLC purity, mass spectrometry sequence confirmation, counter-ions, and endotoxin testing.
Standards for high-performance liquid chromatography (HPLC) peak resolution, relative peak area, and purity quantification.
Defines the International Unit (IU) as a measure of biological activity standardized against physical reference materials.
International dimensional and graduation specification for U-100 and U-40 insulin syringes (0.3 mL, 0.5 mL, and 1.0 mL).
Manufacturer Device & Calibrated Syringe Specifications
Manufacturer specifications for sterile single-use U-100 insulin syringes (0.3 mL, 0.5 mL, and 1.0 mL capacities with 1-unit and 1/2-unit scales).
Anti-Doping & International Regulatory Classifications
Prohibits growth hormone secretagogues (GHS), GH fragments, BPC-157, TB-500, and metabolic modulators.
Peer-Reviewed Biomedical & Biochemical Literature
Phase 2 randomized, double-blind, placebo-controlled trial evaluating retatrutide in adults with obesity (PMID: 37364315).
Evaluation of 15-amino acid sequence stability in gastric acid and neutral buffered aqueous solution.
Overview of copper-tripeptide (Gly-His-Lys) biochemistry, chelation thermodynamics, and tissue remodeling.
Primary publication characterizing the 16-amino acid mitochondrial peptide and AMPK activation.
Clinical trial evaluating oral and subcutaneous tolerability without immunogenicity or IGF-1 elevation.
Biochemical characterization of 43-amino acid Tβ4, actin binding via LKKTET motif, and peptide fragments.
Characterization of the C-terminal tripeptide of alpha-MSH (Lys-Pro-Val) and PepT1 intestinal transport.
Clinical pharmacology of the 29-amino-acid synthetic GHRH 1-29 fragment.
Pharmacokinetic and pharmacodynamic characterization of tetra-substituted GHRH 1-29 analogue with DAC.
Notice an outdated citation or regulatory shift?
Submit a correction on our Contact page →